GlassScriptPhysician profile
Jessica Sweetser
NPI 1891329330
$995.89
in general payments reported to CMS, 2019-2025
11 companies · $817 in 2025
The $817 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $179 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $696.91 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $298.98 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $179.11 | 2023 | Opdivo, Reblozyl |
| Pharmaessentia USA Corporation | $125.00 | 2025 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2025 | |
| Adaptive Biotechnologies Corporation | $75.13 | 2025 | Clonoseq |
| Emd Serono, INC. | $59.06 | 2025 | |
| Tempus Ai, INC | $48.91 | 2025 | Xt Cdx |
| Stemline Therapeutics INC. | $29.41 | 2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $23.81 | 2025 | |
| Novocure INC. | $21.90 | 2025 | Optune Lua (Novottf-200t) |
| Pfizer INC. | $9.58 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Sweetser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.